Hospital
Bethesda Hospital INC
Bethesda Hospital INC was paid $57.06M by Medicaid between Jan 2018 and Dec 2024, across 452 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoBETHESDA HOSPITAL INC
CINCINNATI, OH 45242
CINCINNATI, OH 45242
33aNPI1396714663assigned 03/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$57.06M
24GClaims1,638,177
24DCodes billed452
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#18 of 101
Median peer was paid$22.32M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110,220 | $3.65M | |
| 2019 | 88,851 | $3.16M | |
| 2020 | 82,546 | $4.26M | |
| 2021 | 113,366 | $4.97M | |
| 2022 | 150,625 | $6.62M | |
| 2023 | 613,435 | $20.22M | |
| 2024incomplete | 479,134 | $14.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 90,496 | 82,793 | $10.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 59,009 | 52,386 | $8.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 18,947 | 15,177 | $5.88M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.7% | 15,663 | 13,552 | $2.08M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.6% | 11,200 | 7,949 | $1.50M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.5% | 11,852 | 8,967 | $1.45M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 5,833 | 4,611 | $1.39M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 5,295 | 4,300 | $1.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 9,351 | 7,382 | $1.11M |
| 80053 | Comprehensive metabolic panel | 1.6% | 40,708 | 37,546 | $891K |
| 59025 | Fetal non-stress test | 1.2% | 4,336 | 2,911 | $702K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 17,076 | 15,438 | $647K |
440 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 28,588 | $645K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 4,216 | $586K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 2,152 | $584K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,635 | $539K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 744 | $535K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,968 | $534K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,150 | $503K |
| G0378 | Hospital observation service, per hour | <1% | 7,054 | $461K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,124 | $460K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,617 | $458K |
| 80061 | Lipid panel | <1% | 28,713 | $431K |
| 58661 | <1% | 280 | $420K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 109,679 | $392K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,691 | $387K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,547 | $377K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,860 | $362K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17,004 | $349K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,872 | $342K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,935 | $339K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 24,488 | $330K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 980 | $324K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 72,145 | $323K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,081 | $301K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 8,641 | $295K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,013 | $291K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 28,351 | $269K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 401 | $264K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 14,627 | $263K |
| 95811 | <1% | 371 | $261K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 224 | $251K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,024 | $229K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,025 | $228K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 6,975 | $212K |
| 82607 | <1% | 8,231 | $188K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 405 | $184K |
| 70496 | <1% | 1,069 | $181K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,640 | $179K |
| 85027 | <1% | 19,215 | $179K | |
| 86850 | <1% | 8,596 | $176K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 312 | $174K |
| 36415 | Collection of venous blood by venipuncture | <1% | 138,300 | $173K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 630 | $171K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 952 | $164K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 2,406 | $157K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 9,227 | $154K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 438 | $146K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 848 | $130K |
| 76642 | <1% | 931 | $116K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,545 | $114K |
| 87070 | <1% | 9,086 | $112K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,775 | $111K |
| 80047 | <1% | 6,503 | $108K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,169 | $108K |
| 80076 | <1% | 26,452 | $106K | |
| 82728 | <1% | 5,520 | $106K | |
| 84439 | <1% | 5,601 | $97K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 668 | $96K |
| 86762 | <1% | 4,136 | $96K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 622 | $95K |
| 76818 | <1% | 796 | $93K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 59 | $93K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,185 | $91K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 858 | $86K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,119 | $85K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 757 | $82K |
| 71250 | <1% | 762 | $82K | |
| 86780 | <1% | 5,422 | $81K | |
| 83540 | <1% | 7,402 | $81K | |
| 12001 | <1% | 539 | $79K | |
| 81514 | <1% | 907 | $75K | |
| 86900 | <1% | 8,716 | $75K | |
| 84702 | <1% | 3,907 | $70K | |
| 87077 | <1% | 7,116 | $70K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 551 | $70K |
| 82570 | <1% | 6,804 | $68K | |
| 11045 | <1% | 202 | $68K | |
| 93017 | <1% | 783 | $66K | |
| 10060 | <1% | 425 | $66K | |
| 83550 | <1% | 6,483 | $63K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,474 | $61K |
| 84153 | <1% | 2,695 | $60K | |
| 87653 | <1% | 1,825 | $59K | |
| 93971 | <1% | 775 | $57K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,711 | $55K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,142 | $53K |
| 84484 | <1% | 15,759 | $52K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,567 | $50K |
| 11043 | <1% | 332 | $48K | |
| 87205 | <1% | 5,876 | $48K | |
| 72141 | <1% | 295 | $45K | |
| 94060 | <1% | 404 | $45K | |
| 87340 | <1% | 2,818 | $44K | |
| 88307 | <1% | 571 | $44K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 706 | $43K |
| 97162 | <1% | 941 | $43K | |
| 76536 | <1% | 380 | $41K | |
| 86481 | <1% | 1,010 | $40K | |
| 82043 | <1% | 4,958 | $40K | |
| 86901 | <1% | 8,717 | $40K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 29,818 | $40K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,383 | $39K |
| 70491 | <1% | 144 | $39K | |
| 86140 | <1% | 4,534 | $39K | |
| 47562 | <1% | 20 | $36K | |
| 87186 | <1% | 5,216 | $35K | |
| 83970 | <1% | 1,051 | $35K | |
| 81001 | <1% | 34,736 | $35K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 857 | $35K |
| 83001 | <1% | 1,213 | $35K | |
| 82746 | <1% | 3,030 | $34K | |
| 87481 | <1% | 1,584 | $34K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 258 | $33K |
| 76830 | Ultrasound, transvaginal | <1% | 880 | $32K |
| 71271 | <1% | 203 | $32K | |
| 72100 | <1% | 1,776 | $32K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,034 | $32K |
| 70498 | <1% | 1,047 | $30K | |
| 82950 | <1% | 3,386 | $30K | |
| 83735 | <1% | 8,604 | $30K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,358 | $29K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 35,023 | $27K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,477 | $25K |
| 87522 | Neg quan hep c or qual rna | <1% | 744 | $25K |
| 93458 | <1% | 17 | $25K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,415 | $24K |
| 90715 | <1% | 1,739 | $24K | |
| 76801 | <1% | 159 | $24K | |
| 84144 | <1% | 876 | $24K | |
| 97163 | <1% | 758 | $23K | |
| 87625 | <1% | 1,084 | $23K | |
| 94727 | <1% | 447 | $23K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 498 | $22K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 323 | $22K |
| 93970 | <1% | 163 | $22K | |
| 96367 | <1% | 569 | $22K | |
| 76775 | <1% | 218 | $22K | |
| 70486 | <1% | 323 | $21K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 115 | $21K |
| 80320 | <1% | 2,299 | $21K | |
| 86038 | <1% | 1,134 | $21K | |
| 74018 | <1% | 886 | $21K | |
| 84146 | <1% | 1,002 | $20K | |
| 58563 | <1% | 18 | $20K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 25,638 | $20K |
| 94729 | <1% | 445 | $19K | |
| 82565 | <1% | 2,976 | $19K | |
| 12011 | <1% | 132 | $19K | |
| 73560 | <1% | 1,644 | $19K | |
| 84403 | <1% | 1,066 | $19K | |
| 12002 | <1% | 139 | $18K | |
| 80069 | <1% | 1,329 | $18K | |
| 88341 | <1% | 400 | $18K | |
| 77062 | <1% | 458 | $18K | |
| 81025 | <1% | 30,073 | $18K | |
| 85610 | <1% | 6,316 | $17K | |
| 97167 | <1% | 555 | $17K | |
| 77080 | <1% | 239 | $17K | |
| 84481 | <1% | 588 | $17K | |
| 72040 | <1% | 898 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,610 | $16K |
| 80074 | <1% | 756 | $15K | |
| 73630 | <1% | 1,914 | $15K | |
| 83525 | <1% | 599 | $15K | |
| S5161 | Emergency response system; service fee, per month (excludes installation and testing) | <1% | 486 | $15K |
| 85652 | <1% | 3,047 | $15K | |
| 97113 | <1% | 158 | $15K | |
| 88342 | <1% | 911 | $15K | |
| 87088 | <1% | 1,932 | $15K | |
| 73030 | <1% | 1,392 | $15K | |
| 96376 | <1% | 4,497 | $15K | |
| 93976 | <1% | 143 | $15K | |
| 86695 | <1% | 848 | $15K | |
| 84550 | <1% | 2,614 | $14K | |
| 84100 | <1% | 2,326 | $14K | |
| 83880 | <1% | 3,389 | $14K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 76 | $14K |
| 29580 | <1% | 106 | $14K | |
| 97014 | <1% | 398 | $13K | |
| 83516 | <1% | 703 | $13K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 359 | $13K |
| 86696 | <1% | 848 | $13K | |
| 87255 | <1% | 263 | $13K | |
| 86431 | <1% | 922 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,135 | $12K |
| 83690 | <1% | 18,469 | $12K | |
| 86706 | <1% | 660 | $12K | |
| 82951 | <1% | 509 | $12K | |
| 73610 | <1% | 1,560 | $12K | |
| J3490 | Unclassified drugs | <1% | 2,818 | $11K |
| 82962 | <1% | 8,029 | $11K | |
| 93880 | <1% | 165 | $11K | |
| 73130 | <1% | 1,249 | $11K | |
| 82670 | <1% | 676 | $11K | |
| 84402 | <1% | 607 | $11K | |
| 77065 | Tomosynthesis, mammo | <1% | 509 | $11K |
| 58558 | <1% | 13 | $11K | |
| 82550 | <1% | 1,539 | $11K | |
| 83002 | <1% | 629 | $11K | |
| 84270 | <1% | 566 | $11K | |
| 86200 | <1% | 604 | $10K | |
| 83020 | <1% | 455 | $10K | |
| 84156 | <1% | 2,082 | $10K | |
| 88304 | <1% | 981 | $10K | |
| 97116 | <1% | 960 | $10K | |
| 74183 | <1% | 43 | $10K | |
| 87493 | <1% | 326 | $10K | |
| 81002 | <1% | 12,709 | $9K | |
| 83615 | <1% | 1,868 | $9K | |
| 84460 | <1% | 1,913 | $9K | |
| 87510 | <1% | 294 | $9K | |
| 84450 | <1% | 1,823 | $8K | |
| 86704 | <1% | 409 | $8K | |
| 82627 | <1% | 278 | $8K | |
| 82247 | <1% | 1,586 | $8K | |
| 95816 | <1% | 46 | $8K | |
| 76820 | <1% | 124 | $8K | |
| 62323 | <1% | 19 | $8K | |
| 73502 | <1% | 879 | $8K | |
| 73110 | <1% | 904 | $7K | |
| 82784 | <1% | 587 | $7K | |
| 87109 | <1% | 353 | $7K | |
| 93226 | <1% | 70 | $7K | |
| 86235 | <1% | 514 | $7K | |
| 72131 | <1% | 107 | $7K | |
| 77066 | Tomosynthesis, mammo | <1% | 529 | $7K |
| 82952 | <1% | 503 | $7K | |
| 93325 | <1% | 141 | $7K | |
| 72070 | <1% | 399 | $7K | |
| 73562 | <1% | 580 | $7K | |
| 86364 | <1% | 310 | $6K | |
| 00840 | <1% | 818 | $6K | |
| 64483 | <1% | 17 | $6K | |
| 77061 | <1% | 171 | $6K | |
| 82533 | <1% | 296 | $6K | |
| 82525 | <1% | 272 | $6K | |
| 86694 | <1% | 324 | $6K | |
| 86376 | <1% | 274 | $6K | |
| 85730 | <1% | 4,042 | $6K | |
| 84425 | <1% | 381 | $6K | |
| 86225 | <1% | 326 | $5K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 1,950 | $5K |
| 87480 | <1% | 294 | $5K | |
| 84520 | <1% | 1,355 | $5K | |
| 85045 | <1% | 1,015 | $5K | |
| 97166 | <1% | 97 | $5K | |
| 87660 | <1% | 321 | $5K | |
| 82105 | <1% | 171 | $5K | |
| 83722 | <1% | 384 | $4K | |
| 83605 | <1% | 4,172 | $4K | |
| 81003 | <1% | 6,947 | $4K | |
| 73070 | <1% | 593 | $4K | |
| 86161 | <1% | 217 | $4K | |
| 86787 | <1% | 185 | $4K | |
| 87902 | <1% | 26 | $4K | |
| 87536 | <1% | 70 | $4K | |
| 93225 | <1% | 39 | $4K | |
| 86039 | <1% | 136 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,650 | $4K |
| 83520 | <1% | 137 | $4K | |
| 86361 | <1% | 55 | $3K | |
| 90686 | <1% | 154 | $3K | |
| 93242 | <1% | 51 | $3K | |
| 87045 | <1% | 200 | $3K | |
| 58300 | <1% | 32 | $3K | |
| 00790 | <1% | 87 | $3K | |
| 86160 | <1% | 216 | $3K | |
| 73140 | <1% | 468 | $3K | |
| 71100 | <1% | 452 | $3K | |
| 73120 | <1% | 28 | $3K | |
| 85379 | <1% | 2,126 | $3K | |
| 82947 | <1% | 354 | $3K | |
| 73590 | <1% | 385 | $3K | |
| 82664 | <1% | 99 | $3K | |
| 84630 | <1% | 246 | $3K | |
| 86765 | <1% | 88 | $3K | |
| 74019 | <1% | 328 | $3K | |
| 84165 | <1% | 185 | $3K | |
| 87102 | <1% | 570 | $3K | |
| 74174 | <1% | 24 | $3K | |
| 87040 | <1% | 2,090 | $3K | |
| 75574 | <1% | 12 | $3K | |
| 84590 | <1% | 205 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,906 | $2K |
| 86708 | <1% | 113 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 20 | $2K |
| 87046 | <1% | 242 | $2K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 2,485 | $2K |
| 93925 | <1% | 25 | $2K | |
| 84145 | <1% | 809 | $2K | |
| 97161 | <1% | 97 | $2K | |
| 86664 | <1% | 93 | $2K | |
| 73620 | <1% | 38 | $2K | |
| 82150 | <1% | 478 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 100 | $2K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,444 | $2K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 3,157 | $2K |
| 82803 | <1% | 1,739 | $2K | |
| 29125 | <1% | 480 | $2K | |
| 86735 | <1% | 77 | $2K | |
| 86308 | <1% | 228 | $2K | |
| 29515 | <1% | 655 | $2K | |
| 87075 | <1% | 625 | $2K | |
| 80356 | <1% | 151 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,473 | $1K |
| 87430 | <1% | 2,911 | $1K | |
| 82140 | <1% | 326 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,671 | $1K |
| 84445 | <1% | 44 | $1K | |
| 80361 | <1% | 151 | $1K | |
| 80365 | <1% | 151 | $1K | |
| 73090 | <1% | 283 | $1K | |
| 86665 | <1% | 94 | $1K | |
| 87328 | <1% | 96 | $1K | |
| 84681 | <1% | 81 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,123 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 67 | $1K |
| 87210 | <1% | 1,617 | $1K | |
| 86800 | <1% | 73 | $1K | |
| 85014 | <1% | 605 | $1K | |
| 87015 | <1% | 469 | $1K | |
| 86803 | <1% | 82 | $1K | |
| 82248 | <1% | 131 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,533 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,035 | $1K |
| 87329 | <1% | 79 | $1K | |
| 88312 | <1% | 27 | $986.63 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 39 | $956.43 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 836 | $894.16 |
| 82985 | <1% | 71 | $779.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,476 | $744.45 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 118 | $700.57 |
| 86341 | <1% | 16 | $667.59 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,825 | $644.78 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 422 | $640.12 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,265 | $624.75 |
| 83498 | <1% | 38 | $621.22 | |
| 90656 | <1% | 76 | $601.71 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 739 | $551.96 |
| 87116 | <1% | 372 | $551.56 | |
| 82010 | <1% | 587 | $513.14 | |
| 87206 | <1% | 372 | $492.76 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,459 | $453.20 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 183 | $446.07 |
| 80349 | <1% | 39 | $439.93 | |
| 84132 | <1% | 79 | $432.71 | |
| 80143 | <1% | 373 | $418.67 | |
| 88173 | <1% | 30 | $398.03 | |
| 84480 | <1% | 30 | $388.43 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,257 | $384.31 |
| 85018 | <1% | 185 | $377.11 | |
| 76870 | <1% | 13 | $363.90 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,371 | $360.48 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,996 | $344.10 |
| J1815 | Injection, insulin, per 5 units | <1% | 715 | $337.87 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 28 | $312.11 |
| 86870 | <1% | 19 | $297.92 | |
| 80164 | <1% | 33 | $288.05 | |
| 82330 | <1% | 19 | $281.86 | |
| 80329 | <1% | 315 | $273.88 | |
| 82977 | <1% | 28 | $268.68 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,070 | $260.99 |
| 85347 | <1% | 391 | $247.81 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,711 | $246.99 |
| 00952 | <1% | 60 | $246.57 | |
| 86304 | <1% | 13 | $232.26 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 740 | $224.55 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 152 | $221.33 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,084 | $215.10 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 978 | $213.86 |
| 29540 | <1% | 69 | $207.72 | |
| 88302 | <1% | 277 | $199.49 | |
| 86255 | <1% | 16 | $193.22 | |
| 73060 | <1% | 17 | $182.53 | |
| 86698 | <1% | 15 | $182.32 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,758 | $181.57 |
| G0008 | Administration of influenza virus vaccine | <1% | 210 | $167.80 |
| 88112 | <1% | 14 | $162.54 | |
| C1729 | Catheter, drainage | <1% | 120 | $148.32 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 267 | $143.60 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,376 | $142.60 |
| 82270 | <1% | 162 | $138.12 | |
| 88720 | <1% | 46 | $135.63 | |
| 89051 | <1% | 82 | $124.23 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 758 | $106.09 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,384 | $98.34 |
| 82310 | <1% | 13 | $90.43 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 828 | $88.40 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 29 | $88.11 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 379 | $87.64 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 637 | $84.89 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 193 | $84.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 88 | $81.11 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 653 | $78.39 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,163 | $75.29 |
| 84703 | <1% | 14 | $68.84 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 343 | $63.82 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 442 | $54.84 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,117 | $53.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 409 | $52.93 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,219 | $49.09 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 293 | $41.90 |
| Q0114 | Fern test | <1% | 105 | $37.34 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 822 | $37.02 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 53 | $36.41 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 207 | $28.91 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 709 | $26.23 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 267 | $23.41 |
| 93321 | <1% | 13 | $21.66 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 83 | $19.15 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 367 | $15.80 |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 16 | $15.05 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 142 | $13.33 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 106 | $5.02 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 17 | $3.66 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 76 | $1.48 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 451 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,106 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 218 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 446 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 673 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 31 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 21 | $0.00 |
| 43450 | 0% | 63 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 309 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 21 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 12 | $0.00 |
| 29240 | 0% | 20 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 20 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 13 | $0.00 |
| 94760 | 0% | 1,129 | $0.00 | |
| C1769 | Guide wire | 0% | 548 | $0.00 |
| 00126 | 0% | 26 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 372 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 28 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 24 | $0.00 |
| 94761 | 0% | 203 | $0.00 | |
| 77001 | 0% | 65 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 16 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 17 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCROFTON, MICHAEL (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Good Samaritan Hospital of Cincinnati, Ohio | Cincinnati, OH | $85.63M |
| Hospice of Cincinnati Incorporated | Cincinnati, OH | $54.08M |
| Trihealth G LLC | Cincinnati, OH | $30.89M |
| Trihealth H LLC | Cincinnati, OH | $12.50M |
| Mccullough-Hyde Memorial Hospital, INC. | Oxford, OH | $4.51M |
| Trihealth U LLC | Cincinnati, OH | $209K |
| Trihealth HF LLC | Oxford, OH | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.